4.5 Article

Association of copy number variation in the FCGR3B gene with risk of autoimmune diseases

期刊

GENES AND IMMUNITY
卷 11, 期 2, 页码 155-160

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/gene.2009.71

关键词

copy number variation (CNV); FCGR3B; CCL3L1; systemic lupus erythematosus; Sjogren's syndrome

资金

  1. Voelcker Fund Scholar Award
  2. Max and Minnie Tomerlin Voelcker Fund
  3. Elizabeth Glaser Scientist Award
  4. Burroughs Wellcome Clinical Scientist Award in Translational Research
  5. Doris Duke Distinguished Clinical Scientist Award
  6. Rosario University, Bogota, Colombia

向作者/读者索取更多资源

Copy number variation (CNV) in the human genome is an important determinant of susceptibility to autoimmune diseases. Many autoimmune diseases share similar clinical and pathogenic features. Thus, CNVs of genes involved in immunity may serve as shared determinants of multiple autoimmune diseases. Here, we determined the association between CNV in the gene encoding FCGR3B with the risk of developing autoimmune diseases and whether the observed associations are modified by the CNV in CCL3L1 (CC chemokine ligand 3-like 1), a gene encoding a potent chemokine. In a cross-sectional study of 774 subjects, we estimated FCGR3B and CCL3L1 gene copy number in 146, 158 and 61 subjects with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and primary Sjogren's syndrome (SS), respectively, and 409 healthy controls. The median gene dose of FCGR3B in the study population was two. FCGR3B copy number < or >2 was associated with an increased risk of SLE and primary SS but not RA. This association was mostly evident in subjects who also had two copies of CCL3L1. Thus, our data suggest that epistatic interactions between CNV of FCGR3B and CCL3L1, two immune response genes, may influence phenotypically related autoimmune diseases. Genes and Immunity (2010) 11, 155-160; doi:10.1038/gene.2009.71; published online 10 September 2009

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据